Virtual,

Virtual,

Virtual,

US,

ZIP: 00000

Phone: +16174554188

As investments and collaborations hit a record high, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases, exciting efforts have now turned to a wide range of other diseases, from CNS, oncology, metabolism and more. Despite the growing momentum, much needs to be addressed in terms of targeted delivery, safety, and efficiency to fully unleash the therapeutic value of RNAi drugs.

Built with large pharma and pioneering biotech insights, the 2nd RNAi- Based Therapeutics Summit returns virtually in 2021 to reunite key stakeholders of the field to tap into the full therapeutic opportunity of a wide-range of targeted RNAi therapies with enhanced endosomal escape, extrahepatic delivery, and PKPD for CNS, oncology and beyond.

With a number of RNAi based clinical candidates emerging and excitement building in the field, join the 2nd RNAi Based Therapeutic Summit 2020 - the comprehensive industry guide for senior biopharmaceutical leaders from discovery, translation and clinical development functions to stay ahead of the race in developing the first targeted extrahepatic RNAi therapy that addresses unmet patient need.

Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate!

URL:

Tickets: https://go.evvnt.com/733422-0?pid=1052

Greg Hinkle Vice President, Research Informatics Alnylam Pharmaceuticals, Ekkehard Leberer Senior Director, R&D Alliance Management Sanofi, Julia Alterman Senior Scientist Khvorova Lab University of Massachusetts Medical School, Olivia Merkel Professor of Drug Delivery LMU Munich, David Blakey SVP Strategic Alliances MiNa Therapeutics, Yan-Ling He Director of Translational Medicine Novartis Institute for Biomedical Research, Shalini Andersson Chief Scientist New Modalities and Head of Oligonucleotide Discovery AstraZeneca, Arthur Levin Chief Scientific Officer Avidity Biosciences, Julie Lade Senior Scientist Amgen, Dal-Hee Min Chief Technology Officer and Co-Founder Lemonex Inc, Irina Antonijevic Chief Medical Officer Triplet Therapeutics, Guy Hermans Chief Executive Officer Sapreme Technologies, Marcel Blommers Chief Scientific Officer Saverna Therapeutics, Agnes Rafalko Research Director MiNa Therapeutics, Elias Fattal Professor, University of Paris-Saclay, Jolly Mazumdar Founder, President and Chief Scientific Officer Chimeron Bio, Jon Voutila Senior Research Scientist MiNa Therapeutics, June Hyun Park Principal Scientist OliX Pharmaceuticals Inc, Matt Catley Research Director MiNa Therapeutics, Sean Bedingfield Research Engineer New Therapeutic Modalities, Cambridge, Eli Lilly and Company